Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Elderly breast cancer patients benefit from surgery according to guidelines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of two distinct pathways of human myelopoiesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kumar Sanjiv
  • José Manuel Calderón-Montaño
  • Therese M Pham
  • Tom Erkers
  • Viktoriia Tsuber
  • Ingrid Almlöf
  • Andreas Höglund
  • Yaser Heshmati
  • Brinton Seashore-Ludlow
  • Akhilesh Nagesh Danda
  • Helge Gad
  • Elisee Wiita
  • Camilla Göktürk
  • Azita Rasti
  • Stefanie Friedrich
  • Anders Centio
  • Montserrat Estruch
  • Thea Kristin Våtsveen
  • Nona Struyf
  • Torkild Visnes
  • Martin Scobie
  • Tobias Koolmeister
  • Martin Henriksson
  • Olov Wallner
  • Teresa Sandvall
  • Sören Lehmann
  • Kim Theilgaard-Mönch
  • Mathew J Garnett
  • Päivi Östling
  • Julian Walfridsson
  • Thomas Helleday
  • Ulrika Warpman Berglund
Vis graf over relationer

Acute myeloid leukemia (AML) is an aggressive hematological malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential novel target for treating AML. MTH1 prevents incorporation of oxidized nucleotides into the DNA to maintain genome integrity and is upregulated in many cancers. Here we demonstrate that hematological cancers are highly sensitive to MTH1 inhibitor TH1579 (karonudib). A functional precision medicine ex vivo screen in primary AML bone marrow samples demonstrated a broad response profile of TH1579, independent of the genomic alteration of AML, resembling the response profile of the standard-of-care treatments cytarabine and doxorubicin. Furthermore, TH1579 killed primary human AML blast cells (CD45+) as well as chemotherapy resistance leukemic stem cells (CD45+Lin-CD34+CD38-),which are often responsible for AML progression. TH1579 killed AML cells by causing mitotic arrest, elevating intracellular ROS levels, and enhancing oxidative DNA damage. TH1579 showed a significant therapeutic window, was well tolerated in animals, and could be combined with standard-of-care treatments to further improve efficacy. TH1579 significantly improved survival in two different AML disease models in vivo. In conclusion, the pre-clinical data presented here support that TH1579 is a promising novel anticancer agent for AML, providing a rational to investigate the clinical usefulness of TH1579 in AML in an on-going clinical phase 1 trial.

TidsskriftCancer Research
StatusE-pub ahead of print - 30 sep. 2021

ID: 68208182